Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)

被引:18
作者
Choueiri, T. K. [1 ]
Powles, T. B. [2 ]
Albiges, L. [3 ]
Burotto, M. [4 ]
Szczylik, C. [5 ]
Zurawski, B. [6 ]
Riuz, E. Yanez [7 ]
Maruzzo, M. [8 ]
Zaizar, A. Suarez [9 ]
Fein, L. E. [10 ]
Schutz, F. A. Barros [11 ]
Heng, D. Y. C. [12 ]
Wang, F. [13 ,14 ]
Mataveli, F. [13 ]
Chang, Y. L. [14 ]
van Kooten Losio, M. [15 ]
Rodriguez, C. Suarez [16 ]
Motzer, R. J. [17 ]
机构
[1] Harvard Med Sch, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[2] Queen Mary Univ London, St Bartholomews Hosp, Barts Canc Inst, Expt Canc Med Ctr,Dept Genitourinary Oncol, London, England
[3] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[4] Bradford Hill Clin Res Ctr, Oncol, Santiago, Chile
[5] European Hlth Ctr, Ctr Postgrad Med Educ, Dept Oncol, Otwock, Poland
[6] Prof Franciszek Lukaszczyk Oncol Ctr, Dept Outpatient Chemotherapy, Bydgoszcz, Poland
[7] James Lind Ctr Invest Canc, Dept Oncol, Temuco, Chile
[8] IOV IRCCS, Ist Oncol Veneto, Oncol Unit 1, Dept Oncol, Padua, Italy
[9] Consultorio Med Especializada, Dept Oncol, Mexico City, Mexico
[10] Inst Oncol Rosario, Dept Oncol, Rosario, Santa Fe, Argentina
[11] Beneficencia Portuguesa Sao Paulo, Med Oncol, Sao Paulo, SP, Brazil
[12] Univ Calgary, Tom Baker Canc Ctr, Dept Med Oncol, Calgary, AB, Canada
[13] Exelixis Inc, Clin Dev, Alameda, CA USA
[14] Exelixis Inc, Clin Dev, Alameda, CA USA
[15] Bristol Myers Squibb, Clin Dev, Bristol, Switzerland
[16] Hosp Univ Vall DHebron, Vall DHebron Barcelona Hosp Campus, Vall DHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain
[17] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
关键词
D O I
10.1016/j.annonc.2022.08.070
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
LBA8
引用
收藏
页码:S1430 / S1431
页数:2
相关论文
empty
未找到相关数据